SABSW · As filed with the SEC
SAB Biotherapeutics balance sheet, by quarter
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets (Unaudited) · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||
| Cash and cash equivalents | 8,267,000 | 20,519,724 | 10,502,680 | 29,424,708 | 3,692,217 | 5,640,367 | 8,897,966 | 9,171,175 |
| Short-term investments | 94,365,000 | 86,871,857 | 86,089,779 | 81,455,925 | 2,021,335 | 7,209,999 | 11,862,746 | 21,229,472 |
| Accrued interest receivable | 1,844,000 | 1,555,061 | 946,781 | 559,954 | 0 | 21,386 | 54,955 | 97,047 |
| Prepaid expenses and other current assets | 3,461,000 | 3,835,400 | 3,513,384 | 1,836,160 | 3,594,569 | 3,424,957 | 2,976,562 | 2,039,346 |
| Total current assets | 107,937,000 | 112,782,042 | 101,052,624 | 113,276,747 | 9,308,121 | 16,296,709 | 23,792,229 | 32,537,040 |
| Deferred issuance cost | 0 | 0 | 150,145 | 0 | 261,105 | 261,105 | 261,105 | 261,105 |
| Long-term prepaid assets | 5,344,000 | 5,279,709 | 5,309,345 | 124,073 | 156,381 | 188,689 | 220,997 | 253,305 |
| Long-term investments | 105,346,000 | 110,235,540 | 46,892,882 | 50,608,587 | — | — | — | — |
| Operating lease right-of-use assets | 1,901,000 | 2,885,331 | 2,603,059 | 2,806,904 | 3,006,354 | 3,201,514 | 970,294 | 1,064,552 |
| Financing lease right-of-use assets | 3,453,000 | 3,474,306 | 3,496,012 | 3,517,718 | 3,539,423 | 3,561,129 | 3,582,835 | 3,604,541 |
| Property, plant and equipment, net | 14,229,000 | 13,813,570 | 13,305,902 | 13,114,339 | 13,858,104 | 14,610,916 | 15,368,009 | 16,076,640 |
| Total assets | 238,210,000 | 248,470,498 | 172,809,969 | 183,448,368 | 30,129,488 | 38,120,062 | 44,195,469 | 53,797,183 |
| Current liabilities | ||||||||
| Notes payable | — | — | 0 | 0 | 0 | 138,554 | 275,849 | 0 |
| Accounts payable | 3,855,000 | 3,544,958 | 3,145,805 | 2,954,985 | 2,622,357 | 2,520,390 | 1,694,722 | 1,296,987 |
| Accrued expenses and other current liabilities | 7,209,000 | 5,386,530 | 6,583,996 | 6,850,015 | 7,091,760 | 6,055,716 | 5,473,036 | 6,879,750 |
| Operating lease liabilities, current portion | 481,000 | 763,705 | 797,402 | 837,286 | 815,064 | 793,360 | 393,430 | 384,892 |
| Finance lease liabilities, current portion | 160,000 | 156,958 | 153,967 | 151,033 | 148,156 | 145,333 | 142,563 | 139,847 |
| Deferred grant income | — | — | — | — | — | — | 0 | 114,698 |
| Total current liabilities | 11,705,000 | 9,852,151 | 10,681,170 | 10,793,319 | 10,677,337 | 9,653,353 | 7,979,600 | 8,816,174 |
| Operating lease liabilities, noncurrent | 1,451,000 | 2,170,887 | 1,877,360 | 2,037,461 | 2,255,008 | 2,467,223 | 581,148 | 682,925 |
| Finance lease liabilities, noncurrent | 3,040,000 | 3,081,573 | 3,121,952 | 3,161,562 | 3,200,416 | 3,238,531 | 3,275,919 | 3,312,595 |
| Warrant liabilities | 7,229,000 | 6,117,586 | 5,635,112 | 2,381,677 | 1,980,512 | 1,353,456 | 6,389,226 | 4,082,872 |
| Total liabilities | 23,425,000 | 21,222,197 | 21,315,594 | 18,374,019 | 18,113,273 | 16,712,563 | 18,225,893 | 16,894,566 |
| Stockholders equity | ||||||||
| Preferred stock | — | — | — | — | 5 | 5 | 5 | 5 |
| Series A Preferred Stock | 0 | 3 | 3 | 3 | — | — | — | — |
| Preferred Series B | 0 | 59 | 64 | 64 | — | — | — | — |
| Common stock; $0.0001 par value; 800,000,000 shares authorized at June 30, 2026 and December 31, 2025; 83,547,733 and 47,664,564 shares issued at June 30, 2026 and December 31, 2025, respectively, and 83,493,068 and 47,609,899 outstanding at June 30, 2026 and December 31, 2025, respectively | 8,000 | 7,580 | 4,766 | 4,756 | 936 | 936 | 935 | 929 |
| Treasury stock, at cost; 54,665 shares held at June 30, 2026 and December 31, 2025, respectively | (5,521,000) | (5,521,246) | (5,521,246) | (5,521,246) | (5,521,246) | (5,521,246) | (5,521,246) | (5,521,246) |
| Additional paid-in capital | 373,483,000 | 362,748,721 | 267,719,445 | 264,553,973 | 157,032,218 | 156,405,020 | 155,794,142 | 155,144,947 |
| Accumulated other comprehensive income (loss) | (930,000) | (222,764) | 186,510 | 71,223 | (15,805) | (111,593) | (135,410) | 52,133 |
| Accumulated deficit | (152,255,000) | (129,764,052) | (110,895,167) | (94,034,424) | (139,479,893) | (129,365,623) | (124,168,850) | (112,774,151) |
| Total stockholders' equity | 214,785,000 | 227,248,301 | 151,494,375 | 165,074,349 | 12,016,215 | 21,407,499 | 25,969,576 | 36,902,617 |
| Total liabilities and stockholders' equity | 238,210,000 | 248,470,498 | 172,809,969 | 183,448,368 | 30,129,488 | 38,120,062 | 44,195,469 | 53,797,183 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.